Skip to main content

caffeine

Generic: CAFFEINE CITRATE·Brand: Anacin, Anacin Advanced Headache Formula, Arthriten Inflammatory Pain, Ascomp, BC Arthritis, BC Original Formula, Backaid IPF, Backprin, CAFCIT, CAFFEINE CITRATE, Cafcit, Cafergot, Capacet, Dvorah, Esgic, Exaprin, Exaprin Plus, Excedrin, Excedrin Mild Headache, Excedrin Quick Tab, Excedrin Tension Headache, Fioricet, Fioricet with Codeine, Jet-Alert, Migergot, No Doz, Norgesic, Orphengesic, P-A-C Analgesic, Pamprin Max Formula, Panadol Extra, Pep-Back, Repan, Saleto, Sed-Max, Stanback Headache Powder Reformulated Jan 2011, Trezix, Vanatol, Vanquish, Vivarin, Vtol, Zebutal

caffeine: 4 clinical trials tracked.

caffeine evidence translation

What we can confirm

4 tracked trials

No verified listed developer

What it means

AI will separate confirmed drug evidence from unknown company context.

What to watch

Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected

Prepared research question

What is verified about caffeine, and what remains unknown?

Run cited research

Traceable citations · Unknowns marked

See linked entities and source evidence2 indications · 3 study sponsors
Clinical Trials (4)

Effects of Different Caffeine Ingestion Forms on Fat Oxidation During Cycle Ergometer Exercise

Not yet recruiting

Primary endpoint: Rate of fat oxidation during submaximal cycling exercise at Fatmax intensity

InterventionalRandomizeddouble10 targetStarted 2026-02Completion 2026-06Universidad Rey Juan Carlos

A Phase 1, Randomized, Investigator- and Participant-Blinded, Placebo-Controlled, Single- and Multiple-Ascending Dose Study to Characterize the Safety, Tolerability, and Pharmacokinetics of LY4515100 in Healthy Participants and an Open-Label Study to Evaluate the Effect of Itraconazole on the Pharmacokinetics, Safety, and Tolerability of LY4515100 and of LY4515100 on the Pharmacokinetics of CYP and Transporter Substrates in Healthy Participants

NCT07339722·Phase 1·LLY
Recruiting

Primary endpoint: Number of participants with one or more serious adverse event(s) (SAEs) of LY4515100 in Parts A and B

InterventionalRandomizeddouble123 targetStarted 2026-01Completion 2027-031 site · United StatesEli Lilly and Company

A Non-Randomized, Multiple-Dose, Open-Label, Single Sequence Study to Evaluate the Effect of Concomitant Administration of EDP-323 on the Pharmacokinetics and Safety of Midazolam, Caffeine, and Rosuvastatin in Healthy Participants

NCT06917508·Phase 1·ENTA
Completed

Primary endpoint: Cmax of midazolam, caffeine, and rosuvastatin with and without the coadministration of EDP-323

Interventionalopen24 enrolledStarted 2025-03Completion 2025-061 site · United StatesEnanta Pharmaceuticals, Inc

An Open-label, Drug-drug Interaction Study to Investigate the Effects of Amlitelimab on the Pharmacokinetics of Selected Cytochrome P450 Substrates in Adult Participants With Moderate-to-severe Atopic Dermatitis

NCT06686628·Phase 1·SNY
Completed

Primary endpoint: AUC and AUClast for CYP substrates

Interventionalopen23 enrolledStarted 2024-11Completion 2026-041 site · GermanySanofi